The potential value of monitoring bone turnover markers among women on alendronate

Journal of Bone and Mineral Research

Volumn 27, Issue 1, 2012, Pages 195-201

  Bell, Katy J L ^a   Hayen, Andrew ^a   Irwig, Les ^a   Hochberg, Marc C ^b   Ensrud, Kristine E ^c   Cummings, Steven R ^d   Bauer, Douglas C ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Epidemiology; Evidence guidelines; Osteoporosis; Treatments

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; COLLAGEN TYPE 1; CROSS LINKED N TELOPEPTIDE OF TYPE I COLLAGEN; UNCLASSIFIED DRUG;

ARTICLE; BONE TURNOVER; COMPARATIVE STUDY; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONITORING; OSSIFICATION; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT RESPONSE; VERTEBRA FRACTURE;

ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; COLLAGEN TYPE I; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDES; PLACEBOS; REPRODUCIBILITY OF RESULTS;

EID: 84555189306     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.525     Document Type: Article

References (34)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE,. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348 (9041): 1535-41. (Pubitemid 26411651)
2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ,. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280 (24): 2077-82. (Pubitemid 29014065)
3. Bell KJ, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud K, Bauer DC,. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009; 338: b2266.
4. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D,. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000; 283: 1318-21. (Pubitemid 30129799)
5. Pavlic M, Brand B, Cummings S,. Estimating probability of non-response to treatment using mixture distributions. Stat Med. 2001; 20: 1739-53. (Pubitemid 32590950)
6. Chapurlat RD, Palermo L, Ramsay P, Cummings S,. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005; 16: 842-8. (Pubitemid 40933602)
7. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD;, Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial. J Bone Miner Res. 2004; 19: 1250-8. (Pubitemid 41094365)
8. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD,. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 87 (4): 1586-92.
9. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C,. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int. 2001; 12: 922-30. (Pubitemid 34001005)
10. Compston J,. Monitoring osteoporosis treatment. Best Pract Res Clin Rheumatol. 2009; 23: 781-8.
11. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR;, AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 9 (6): 544-64.
12. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. [Internet] Washington, DC: National Osteoporosis Foundation; 2008 [cited 2011 September 29]. Available from:.
13. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy. Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2001; 285 (6): 785-95.
14. Compston J, Cooper A, Cooper C, Francis R, Kanis J, Marsh D, McCloskey E, Reid D, Selby P, Wilkins M, on behalf of the National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009; 62 (2): 105-8.
15. Brown JP, Josse RG;, Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. CMAJ. 2002; 167 (10 Supplement): S1-34. (Pubitemid 35365303)
16. Black DM, Nevitt MC, Cauley J, Karpf D, Cummings SR,. Design of the Fracture Intervention Trial. Osteoporos Int. 1993; 3 (Supplement 3): S29-39.
17. Garnero P, Delmas PD,. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab. 1993; 77: 1046-53. (Pubitemid 23301484)
18. Hanson DA, Weiss MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR,. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992; 7: 1251-8. (Pubitemid 23000964)
19. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD,. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY Study. J Bone Miner Res. 1999; 14 (9): 1614-21. (Pubitemid 29416689)
20. Bell KJL, Irwig L, Craig JC, Macaskill P,. Use of randomized trials to decide when to monitor response to new treatment. BMJ. 2008; 336: 361-5. (Pubitemid 351300370)
21. Goldstein H, Browne W, Rabash J,. Multilevel modelling of medical data. Statistics in medicine. 2002; 21: 3291-315. (Pubitemid 35244014)
22. Singer J, Willet J,. Exploring longitudinal data on change. In: Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press, Inc.; 2003, p. 42-4.
23. Bland JM, Altman DG,. Measurement error proportional to the mean. BMJ. 1996; 313: 106. (Pubitemid 26257767)
24. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L,. Mixed models showed no need for initial response monitoring after starting anti-hypertensive therapy. J Clin Epidemiol. 2009; 62: 650-9.
25. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle J-C,. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause ad response to alendronate therapy. Osteoporos Int. 2000; 11: 295-303. (Pubitemid 30417181)
26. Scarianoa JK, Garryb PJ, Montoyac GD, Wilson JM,. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. Clin Biochem. 2001; 34: 639-44. (Pubitemid 34159355)
27. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut CH 3rd, Eyre DR,. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res. 1994; 9: 135-42. (Pubitemid 24041558)
28. Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, Fressland K, Chesnut C 3rd., Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res. 2000; 15: 594-8. (Pubitemid 30134105)
29. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G,. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone. 1998; 22: 455-61.
30. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C, Hofbauer LC,. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002; 291: 680-6. (Pubitemid 34687400)
31. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ,. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100: 1475-80. (Pubitemid 27425772)
32. Chapurlat RD, Delmas PD,. Drug Insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006; 2 (4): 211-9 [quiz following 238].
33. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J,. Can simple clinical measurements detect patient compliance. Hypertension. 1980; 2: 757-64. (Pubitemid 11180123)
34. Haynes RB, Sackett DL, Taylor DW,. How to detect and manage low patient compliance in chronic illness. Geriatrics. 1980; 35 (1): 91-7.